AstraZeneca says Lynparza combo approved in Japan for certain mCRPC

AstraZeneca (AZN) and MSD’s (MRK) Lynparza in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis, or mCRPC, AstraZeneca announced. Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “This Lynparza combination has been shown to reduce the risk of disease progression or death compared to standard of care and underscores the critical importance of BRCA testing at metastatic diagnosis. Today’s approval is a major step forward for patients in Japan with BRCA-mutated metastatic castration-resistant prostate cancer who urgently need new first-line treatment options.”